Disposition of [¹⁴C]LY2606368 Following Intravenous Administration in Patients With Advanced and/or Metastatic Solid Tumours
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 May 2017
At a glance
- Drugs Prexasertib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 18 May 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Mar 2017 Planned End Date changed from 27 Mar 2018 to 27 Apr 2018.
- 08 Mar 2017 Planned primary completion date changed from 1 Apr 2017 to 28 Apr 2017.